Despite advances in detection and treatment, the 5-year survival rate for lung cancer is still below 20%.
NSCLC accounts for 85% of lung cancer cases, and lung adenocarcinoma is the most common histological subtype. About 30% of lung adenocarcinomas are driven by an activating KRAS mutation. Identify new targets is of paramount importance